148 related articles for article (PubMed ID: 30352905)
1. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Bonnefoi H; Grellety T; Tredan O; Saghatchian M; Dalenc F; Mailliez A; L'Haridon T; Cottu P; Abadie-Lacourtoisie S; You B; Mousseau M; Dauba J; Del Piano F; Desmoulins I; Coussy F; Madranges N; Grenier J; Bidard FC; Proudhon C; MacGrogan G; Orsini C; Pulido M; Gonçalves A
Ann Oncol; 2016 May; 27(5):812-8. PubMed ID: 27052658
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
4. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
6. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
7. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation.
Choi C; Cho WK; Park S; Shin SW; Park W; Kim H; Choi DH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294924
[TBL] [Abstract][Full Text] [Related]
10. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
11. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Guiu S; Charon-Barra C; Vernerey D; Fumoleau P; Campone M; Spielmann M; Roché H; Mesleard C; Arnould L; Lemonnier J; Lacroix-Triki M
Future Oncol; 2015; 11(16):2283-97. PubMed ID: 26260807
[TBL] [Abstract][Full Text] [Related]
15. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
16. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
17. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
[TBL] [Abstract][Full Text] [Related]
18. [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
Héquet D; Mzoughi S; Rouzier R; Guccione E
Bull Cancer; 2017 Apr; 104(4):363-369. PubMed ID: 28216075
[TBL] [Abstract][Full Text] [Related]
19. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.
Chung S; Vail P; Witkiewicz AK; Knudsen ES
Clin Cancer Res; 2019 Apr; 25(7):2290-2304. PubMed ID: 30538111
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Li W; O'Shaughnessy J; Hayes D; Campone M; Bondarenko I; Zbarskaya I; Brain E; Stenina M; Ivanova O; Graas MP; Neven P; Ricci D; Griffin T; Kheoh T; Yu M; Gormley M; Martin J; Schaffer M; Zelinsky K; De Porre P; Johnston SR
Clin Cancer Res; 2016 Dec; 22(24):6002-6009. PubMed ID: 27267854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
